$BHST

Tiziana Life Sciences (TLSA) received a Buy rating and $7 price target from BTIG. Ocean Power Technologies (OPTT) is using Palantir Foundry to improve operations. Sintana Energy (SEI) reported TotalEnergies' acquisition of a 40% interest in Namibia’s PEL 83. American Resources (AREC) joined the Critical Minerals Institute. Thistle Resources (TRCG) launched a Phase 3 drill program. BioHarvest Sciences (BHST) plans to dual-list on the Tel Aviv Stock Exchange. Alvopetro Energy (ALV) reported August

BioHarvest Sciences (NASDAQ: BHST) plans to list its shares on the Tel Aviv Stock Exchange (TASE) by September 8, 2026, alongside its Nasdaq listing. The company, which develops plant-based molecules, aims to provide Israeli investors with access to its shares. BioHarvest filed to register 22.67 million outstanding shares and up to 5.13 million additional shares. CEO Zaki Rakib stated this move supports the company's growth and global ambitions.

BioHarvest Sciences (BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year over year, with gross profit of $5.1 million and a net loss of $3.7 million ($0.17/share). Cash rose to $16.2 million. The company revised 2026 revenue guidance to $37 million to $40 million and expects consolidated EBITDA losses of $3 million to $5 million, citing a shift toward CDMO growth and a rare fragrance supply agreement.

US stocks ended lower as US-Iran talks remained unresolved amid Strait of Hormuz uncertainty. The Nasdaq fell 0.6% to 26,445, while the Dow and S&P 500 each declined 0.3%. Oil was steady near $82.50/bbl, according to IG’s Axel Rudolph. The article also cites company-specific moves including Nvidia’s $500B AI financing plan and several earnings, bids, and guidance updates.

BIOHARVEST SCIENCES INC. (BHST) furnished an SEC Form 6-K — earnings release. BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update - Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable

BioHarvest Sciences reported a Q2 2026 earnings call focused on shifting capital from D2C to CDMO. It secured a CDMO manufacturing and supply deal for a rare fragrance, targeting $20m to $30m revenue in 2027-2028 and $180m over five years, with limited production in H1 2027. 2026 revenue guidance was cut to $37m-$40m, and it expects CDMO EBITDA loss of $1.5m-$2.5m and consolidated EBITDA breakeven in 2027.

BioHarvest Sciences (BHST) reported Q2 revenue of $8.8M, up 3.8% y/y, with net loss of $3.7M ($0.17/sh) versus $4.1M ($0.24/sh) a year earlier. Operating expenses rose to $7.6M. Cash and equivalents plus deposits were $16.25M at June 30. It tightened CDMO guidance to $4M-$5M and cut VINIA guidance to $33M-$35M, and signed a UAE customer deal for 20 tons of a fragrance ingredient starting as early as H1 2027.

BioHarvest Sciences Inc (NASDAQ: BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year over year, with 58% gross margin. The company said it secured its first CDMO manufacturing and supply agreement for a UAE fragrance ingredient, targeting up to 20 tons over two years, with limited production possibly starting in H1 2027. It also received a $1.4M Israel Innovation Authority grant.

BioHarvest Sciences (NASDAQ:BHST) said it received a 4.33 million NIS (about $1.4 million) grant from Israel Innovation Authority to fund an AI and computer-vision initiative for its plant cell culture programs. The non-dilutive, zero-interest loan supports integrating data science, chemo-informatics and digital sensing to build a computational discovery engine. Repayment depends on commercial milestones and future revenues.

BioHarvest Sciences (NASDAQ: BHST) said the Israel Innovation Authority approved a 4.33 million NIS (about $1.4 million) non-dilutive, zero-interest grant to fund an AI and data-science initiative for plant-cell culture optimization. The company said the second IIA grant this year supports predictive machine learning and digital sensing, with repayment tied to commercial milestones.